1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
OncoVista Innovative Therapies, Inc.

OncoVista Innovative Therapies, Inc.

OVIT
OncoVista Innovative Therapies, Inc.US flagOther OTC
0.00
USD
- -
- -
2,356.00Market Cap
OncoVista Innovative Therapies, Inc.
OVIT
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
TTM
FRC
- -
0.01
0.11
0.11
0.03
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.03
-0.02
-0.51
-0.33
-0.41
-0.26
0.49
-0.1
-0.08
-0.07
-0.12
-0.15
Basic EPS, GAAP
-0.01
-0.01
-0.17
-0.17
-0.21
-0.05
-0.03
-0.08
-0.07
-0.02
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.14
-0.15
-0.62
-0.94
-1.29
-1.54
-0.89
-0.95
-1.02
-1.08
-1.2
-1.2
Book Value per Share
-0.08
-0.09
-0.33
-0.23
-0.46
-0.61
0.08
-0.01
-0.08
-0.14
-0.26
-0.29
Tangible Book Value per Share
17
17
17
17
18
18
20
21
22
22
22
22
Basic Weighted Avg Shares
- -
- -
2
2
1
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-540.65
-205.62
-191.12
-311.09
-1,591.7
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
-9
-6
-7
-5
10
-2
-2
-1
-3
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-568.76
-184.58
-449.72
-307.65
-1,486.52
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1
-2
-1
- -
-5
-11
2
- -
-2
-3
-5
-6
Working Capital
- -
- -
5
4
4
- -
- -
- -
- -
- -
- -
- -
LT Debt
-1
-2
-6
-4
-8
-11
2
- -
-2
-3
-6
-7
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
24
Market Capitalization
10
20
9

Working Capital

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
6
6
Payables & Accruals
3
4
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
158.94%
239.8%
81.53%
Free Cash Flow
235.42%
5.49%
-50.22%
Net Income, GAAP
260.48%
-77.27%
75.52%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
-0.02
-0.01
-0.02
- -
-0.07
2014
-0.01
-0.04
0.01
- -
-0.12
2015
-0.01
-0.05
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
Similar Companies
GeneReach Biotechnology Corp. (4171.TWO)
AEON Biopharma, Inc. (AEON)
Hexima Limited (HXL.AX)
PreveCeutical Medical Inc. (PRVCF)
Allena Pharmaceuticals, Inc. (ALNAQ)
Sprint Bioscience AB (SPRINT.ST)
Business
OncoVista Innovative Therapies, Inc. (OVIT) is a biopharmaceutical company that develops targeted anticancer therapies utilizing tumor-associated biomarkers. Founded in 2004 and headquartered at 14785 Omicron Drive, Suite 104, San Antonio, Texas, the company focuses on oncology drug candidates including Cordycepin (OVI-123), in Phase I/II clinical trials for refractory TdT-positive leukemias; L-Nucleoside Conjugates (OVI-117), under preclinical development as a thymidylate synthase inhibitor for colon cancer and other solid tumors such as breast, gastric, and prostate; and OSI-7904L, a discontinued candidate previously advanced for biliary tract neoplasms. It operates in the biotechnology segment of the healthcare industry, primarily targeting patients with metastatic and refractory cancers through biomarker-driven approaches that aim to enhance efficacy and reduce toxicity, with activities centered in the United States. The company maintains a small team of two employees led by CEO Alexander Weis and trades on OTC Markets under the ticker OVIT. No major recent partnerships, funding rounds, acquisitions, new product launches, or strategic shifts have been reported in the last one to two years, with development efforts appearing dormant following historical activities such as the 2012 FDA IND approval for OVI-117 and earlier financings.